Drug Discovery & Development Products & Reviews

LUMOS II ILIM redefines infrared imaging speed and precision. With patented Infrared Laser Imaging technology, it delivers hyperspectral data at a pace that transforms workflows: what used to take months can now be done in days. It’s not just faster—it’s smarter, combining automation, AI-driven analysis, and multimodal imaging for research and routine applications alike.

Cryopreserved, highly reproducible patient-derived organoids ready for immediate use

Streamline Mass Spec Sample Preparation. MassXtract STAR Line combines all the tools you need to fully automate solid-phase extraction and protein precipitation workflows.

Reliable GC workflows for every lab.

Pharmacokinetics (PK) is a crucial part of biopharmaceutical toxicology that evaluates the absorption, distribution, metabolism, and excretion (ADME) of biotherapeutics. Prolytix offers robust PK assays to support preclinical and clinical phases of biotherapeutic development.

GMP release testing is a critical quality control process that ensures manufactured therapeutics meet predetermined specifications before release. Prolytix provides GMP release testing for clinical and commercial drug substances and drug products.

GMP stability testing determines how a drug product performs under routine and stressed conditions. Prolytix performs GMP‑compliant stability testing and provides ICH‑compliant storage to support clinical and commercial drug products.

Protein characterisation services provide detailed analysis of critical attributes of large‑molecule therapeutics, delivering high‑quality data to support development decision‑making and regulatory submissions

Process development services support the isolation, purification, and optimisation of large‑molecule drug manufacturing processes. Prolytix provides consultative process development to support efficient biologic development

Biomarker assays are laboratory methods that detect or analyse genes, proteins, or other molecules in biological samples and are fundamental tests in biotherapeutic drug monitoring, research, and development. Prolytix offers comprehensive biomarker assay development, validation, and testing services.

Immunogenicity assays are critical assessments that screen for potential anti‑drug antibodies (ADAs) and support product safety and efficacy. Prolytix supports partners with comprehensive immunogenicity method development, validation, and testing for preclinical and clinical phases of biotherapeutic development.

Prolytix provides custom bioanalytical method development and validation services to support large‑molecule drug products, delivering relevant and reliable data for preclinical, clinical, and CMC studies.

Designed for accuracy and speed, Omnia Discovery optimizes workflows, reduces reagent waste, and offers value for advancing microfluidic and assay development.‍

The Queen of high-throughput protein stability characterization. Aunty is the fastest and highest throughput protein stability characterization tool on the planet.

A suite of bioinformatics pipelines to process NGS data and maximise genomic discovery.

Submicron resolution and high sample throughput deliver exceptional data quality and rapid scan times.

Illumina 5-base solution for methylation and variant detection

The NovaSeq X and NovaSeq X Plus Sequencing Systems deliver extraordinary throughput and accuracy to perform data-intensive applications at production scale.

Expansive application breadth and operational simplicity with proven performance

Integrated IND-enabling development for small molecules, with GMP API and drug product, GLP safety, DMPK and bioanalysis under one roof.

GLP and GCP bioanalysis for small molecules, biologics, oligonucleotides and cell and gene therapies, with LC-MS/MS and ligand binding assays covering method development, validation, immunogenicity and preclinical to Phase IV sample analysis.

End-to-end early clinical development, from first-in-human and proof-of-concept trials to regulatory submissions, biomarker translation, bioanalysis and clinical supply, delivered by one senior team with a single point of contact.

Tailored de-risking for a shortlist of mainly small molecule candidates, assessing API developability, formulation, DMPK and in vitro and in vivo safety to confirm the right clinical candidate before IND-enabling investment.

Integrated biostatistics, clinical data management, CDISC data standardization and PK/PD modeling to turn preclinical and clinical study data into submission-ready, decision-grade results, from early discovery through Phase III.

In vitro toxicity screening in 3D microtissue, spheroid and multilayer cell models of liver, heart, brain and intestine, supporting repeat-dose studies with high content imaging and biochemical endpoints for more human-relevant safety data.